uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted January 12, 2023

FDA Warns Two Sellers Promoting CBD to Treat COVID-19

On January 10, 2023, the FDA issued warning letters to two companies following a review that found statements made on the companies’ websites to be drug claims because they promoted the cannabidiol (CBD) products to prevent or treat COVID-19.

To see the warning letter for each product, click the link below.

  • Medical Mikes, Inc.: Products were promoted with statements such as “…highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.”
  • Purecraft, LLC: Company products were promoted with statements such as, “Early results show that therapeutic doses of CBD do have a protective effect against COVID. . . . According to the National Institute of Health’s COVID-19 Research initiative…” and “Hypothesis #2: CBD May Reduce Inflammation Related To COVID-19.”

The FDA instructed the companies to immediately cease and desist making these claims. The companies are also required to send an email to within 48 hours of receipt of the warning, describing the specific steps taken to correct any violations.

For more information and tests of related products, see ConsumerLab’s CBD & Hemp Extract Supplements, Lotions, and Balms Review.

Also see Do any supplements help with coronavirus (COVID-19)? Do supplements like vitamin D, zinc, vitamin C, or herbals work?

See related recalls and warnings:

Seller of CBD Warned for COVID-19 Claims

CBD Not Permitted in Gummies, Candies, Cookies, Candy, or Pet Treats, Says FDA

CBD Products Were Promoted to Treat Cancer and Alzheimer’s Without Proof, Says FTC

Maker of Care by Design CBD Settles Charges of Unsupported Claims

CBD Seller Warned for Drug and COVID-19 Claims